Cencora, Inc. announced on January 2, 2025, the completion of its acquisition of Retina Consultants of America (RCA). Cencora acquired an approximate 85% interest in RCA, with a cash outlay of $4.4 billion at closing, after accounting for an equity rollover, cash capitalization, transaction fees, and debt repayment.
This acquisition is a strategic move to build on Cencora's leadership in specialty healthcare and expand its Managed Service Organization (MSO) solutions. The company expects the integration of RCA to drive differentiated value for stakeholders, including physicians and patients.
Following the closing of the RCA acquisition and continued momentum in the U.S. Healthcare Solutions segment, Cencora updated its fiscal year 2025 adjusted diluted EPS guidance. The new range is $15.15 to $15.45, raised from the previous range of $14.80 to $15.10.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.